These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27755244)

  • 1. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
    Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e64-e75. PubMed ID: 27755244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
    Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S64-75. PubMed ID: 27183527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.
    Deidda M; Madonna R; Mango R; Pagliaro P; Bassareo PP; Cugusi L; Romano S; Penco M; Romeo F; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e76-e83. PubMed ID: 27755245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
    Yun S; Vincelette ND; Abraham I
    Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardioprotection in women with neoplastic disease].
    Cardinale D; Colombo A; Bacchiani G
    G Ital Cardiol (Rome); 2012 Jun; 13(6):461-8. PubMed ID: 22622126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anthracycline-induced cardiomyopathy].
    Roul G; Cohen C; Lieber A
    Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
    Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of anthracycline cardiotoxicity].
    Rossetti R
    Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
    Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
    Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
    Abdel-Qadir H; Ong G; Fazelzad R; Amir E; Lee DS; Thavendiranathan P; Tomlinson G
    Ann Oncol; 2017 Mar; 28(3):628-633. PubMed ID: 28028033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
    Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.
    Geisberg CA; Sawyer DB
    Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.